It is a summer of anticipation for Bostons stem cell medicine biotechnology start-up Asymmetrex. The company has key milestone studies underway for continued development of its unique portfolio of adult tissue stem cell biotechnologies for regenerative medicine and drug development.
Boston, MA (PRWEB) July 29, 2015
Asymmetrex, LLC founder and director James L. Sherley says the company is making good progress in evaluating the full range of capabilities of its unique cache of technologies for identifying, quantifying, and producing adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues and organs. This property makes them the essential therapeutic factor in regenerative medicine treatments developed to restore diseased or injured tissues. The essential role of adult tissue stem cells in maintaining normal tissues also makes them important determinants of drug safety.
Despite the widely understood importance of adult tissue stem cells for advancing biomedicine, in the past, implementation of this knowledge has been largely unachievable because of long-standing technology barriers. In many cases, adult tissue stem cells have been difficult to identify, impossible to count, and difficult to produce in therapeutic quantities. These significant technical challenges have limited regenerative medicine treatments to only a few tissue stem cell types and essentially precluded evaluation of drug candidate effects on critical tissue stem cell types.
Says Sherley, Asymmetrex seeks to catalyze a new era of stem cell biomedicine. The company plans to achieve catalysis by reaching a tipping point for the widespread use of its patented technologies for identifying, counting, and producing adult tissue stem cells from many different human tissues. In addition, because Asymmetrexs technologies are based on universal tissue stem cell principles, they also have application for animal research and veterinary medicine.
Director Sherley notes two studies that the company is pursuing this summer that will be completed by early fall and one that will continue until next April, or longer if needed. For its development of adult tissue stem cell production technologies, Asymmetrex is conducting a series of standard pharmaceutical analyses of mature liver cell properties for cells produced from the companys expanded human liver stem cells. Asymmetrex has a patented technology for producing human liver stem cells in pound quantities. Establishing that the expanded liver stem cells can be used to make similarly large quantities of differentiated cells with mature liver functions is an important milestone. This achievement would advance the tissue stem cell expansion technology to applications for pharmaceutical drug evaluations and liver cell transplantation therapies for liver failure patients.
The second summer study is an evaluation of a new technology developed with partner AlphaSTAR Corporation. AlphaSTEM technology is a proprietary human cell culture-computer simulation technology that can estimate and monitor tissue stem cell number, viability, and function for many different human tissues. AlphaSTEM technology could be used to estimate stem cell dose and determine stem cell quality for regenerative medicine stem cell transplantation therapies. Neither of these capabilities currently exists.
A major commercialization thrust of the two partner companies is the use of AlphaSTEM technology to identify tissue stem cell-toxic drug candidates before expensive pre-clinical animal studies and clinical trials. Estimates indicate that, with widespread adoption, the technology could save the U.S. pharmaceutical industry as much as $4 billion each year by preventing expensive testing of drug candidates that would ultimately fail because of toxicity against tissue stem cells. The current study is an evaluation of a panel of known stem cell-activating, stem cell-toxic, and neutral agents designed to begin estimating the predictive power of AlphaSTEM technology.
The third, year-long or greater, study might also yield new developments as soon as the end of the summer. Asymmetrexs most recent patent (U.S. 9,081,008) is for a unique set of biomarkers with sufficient specificity to enable counting of adult tissue stem cells for the first time. In April, the company launched a crowdsourcing campaign to engage investigators worldwide in evaluating its most specific biomarker called H2A.Z asymmetry for counting adult tissue stem cells that are the focus of their research or clinical studies. H2A.Z is a chromosome factor involved in selective gene regulation. In functioning adult tissue stem cells reported to date, it displays a unique pattern that can be used to identify and count tissue stem cells.
Director Sherley is scheduled to discuss the cellular basis of Asymmetrexs biomarkers for counting tissue stem cells and give an update on the progress of the H2A.Z asymmetry crowdsourcing campaign at the 8th International Epigenetics, Stem Cells, Sequencing & SNiPs-2015 Meeting from August 24-25 in Boston. The outcomes from the two summer studies will be reported at BioPharm America 2015, September 15-17, in Boston.
Read this article:
Asymmetrex Plans to Report Results From Adult Stem Cell ...
- CIRI calls for safety advice revamp after health concerns raised by 3D printing emission research - 3D Printing Industry - October 13th, 2022
- Global Adult Stem Cells Market | Expected to Reach USD 9.45 Billion and Compound Annual Growth Rate (CAGR) is - openPR - October 4th, 2022
- The cloudy connection between fragile X and cancer - Spectrum - October 4th, 2022
- CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors - The Fresh Toast - June 22nd, 2022
- How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into 'Safer' Covid-19 Vaccines: Study - ABP Live - June 4th, 2022
- SpaceX capsule returns to Earth with first all-private space station crew Spaceflight Now - Spaceflight Now - May 2nd, 2022
- Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace - April 6th, 2022
- Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies - Business Wire - March 25th, 2022
- Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire - December 24th, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and... - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 8th, 2021
- MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual... - November 8th, 2021
- Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and... - November 8th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021
- A plant that 'cannot die' reveals its genetic secrets - The Independent - August 5th, 2021
- Exploring science with a new generation of girls - US Embassy in Georgia - February 11th, 2021
- Stemcell Renewal Elixir GEORGIA LOUISE - September 25th, 2020
- COVID is shifting the conversation about the medical application of CBD - Open Access Government - September 22nd, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 22nd, 2020
- Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer - Yahoo... - June 6th, 2020
- Athens hospital using biologic treatment on COVID-19 patients - Online Athens - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- Novant Health Initiates Phase 2b/3 Trial with CytoDyns Leronlimab for Severely and Critically Ill COVID-19 Patients - Yahoo Finance - May 11th, 2020
- CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -... - May 5th, 2020
- Covid-19 has shuttered labs. It could put a generation of researchers at risk - STAT - May 5th, 2020
- CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable... - May 5th, 2020
- Stem Cell Therapy in Atlanta, GA - sipapain.com - February 3rd, 2020
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 - News Distribute - December 27th, 2019
- Transition to exhaustion: clues for cancer immunotherapy - 7thSpace Interactive - December 5th, 2019
- Autologous Stem Cell And Non Stem Cell Based Therapies Market Opportunity Analysis and Industry Forecast up to 2026 - Guru Online News - November 20th, 2019
- Georgia solar factory scores on tariffs; others in industry take a hit - Atlanta Journal Constitution - September 23rd, 2019
- Georgia Stem Cells | Stem Cell TV - September 7th, 2019
- Current Strategies and Challenges for Purification of ... - March 6th, 2019
- Stem Cell Savannah Georgia 31401 - January 20th, 2019
- Atlanta, Georgia Stem Cell Transplant, Marietta, Berkeley ... - September 7th, 2018
- Placenta | Amniotic tissue is not stem cell therapy - Dr ... - July 17th, 2018
- Turning Skin Cells Into Brain Cells - 06/28/2012 - October 1st, 2017
- This Wasp's Larvae Sometimes Grow Hundreds of Soldier ClonesBut Why? - Entomology Today - August 21st, 2017
- Atlanta Stem Cell Therapy | Georgia Stem Cell Treatments ... - October 7th, 2016
- Storing Stem Cells In Teeth For Your Familys Future Health - October 31st, 2015
- Scientists Turn Back the Clock on Adult Stem Cells Aging ... - October 16th, 2015
- Lymphoid Cells, Lymphoid Stem Cells - AllCells.com - October 11th, 2015
- Using Stem Cells in Teeth for Future Use in Developing ... - September 30th, 2015
- Human Mesenchymal Stem Cells & Media - September 25th, 2015
- Stem Cells - Lonza - July 10th, 2015
- Global Stem Cells Group Announces First Stem Cell Training ... - June 3rd, 2015
- Effective Hematopoietic Mesenchymal Stem Cell Therapies - April 25th, 2015
- Stem Cells Hashimoto's Thyroiditis - April 22nd, 2015
- Welcome to Atlanta Stem Cell Treatment - April 9th, 2015
- Stem Cells Thailand - Stem Cell Therapy Thailand - March 27th, 2015
- Stem Cell Institute Los Angeles Chronic Pain Treatments - March 27th, 2015
- Graphene Shows Promise In Eradication Of Stem Cancer Cells - March 10th, 2015
- Stem Cell Treatment India,Stem Cell Treatment India,Cost ... - March 8th, 2015
- Bone Marrow & Stem Cell Transplant Center | Atlanta, GA ... - November 16th, 2014
- Biological fat with a sugar attached essential to maintaining the brain's supply of stem cells - November 3rd, 2014
- How stress ups depression risk - October 21st, 2014
- Protein appears to protect against bone loss in arthritis - September 13th, 2014
- Boron Facilitates Stem Cell Growth and Development in Corn - August 29th, 2014
- Georgia (Stem Cell) - what-when-how - August 26th, 2014
- Stem Cells in GA - Georgia Bio - August 25th, 2014
- Stem Cells COPD | Stem Cell Treatments - August 23rd, 2014
- Stem Cells Atlanta GA, Stem Cell Therapy, Dental Stem Cells - August 22nd, 2014
- Stem cells reveal how illness-linked genetic variation affects neurons - August 22nd, 2014